Company news
Tango Therapeutics, Inc. (NASDAQ:TNGX) news
Every Tango Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Tango Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
September 1, 2026
Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
August 11, 2026
Tango Therapeutics Appoints Robert Azelby to Board of Directors
June 22, 2026
Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering
June 9, 2026
Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer
June 8, 2026
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
May 13, 2026
Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat
April 15, 2026
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
March 5, 2026
Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights
March 5, 2026
Tango Therapeutics to Report Fourth Quarter 2025 Financial Results and Participate in Three Upcoming Investor Conferences
February 18, 2026
Tango Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 3, 2026
Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor
January 8, 2026
Tango Therapeutics Appoints Sung Lee to Board of Directors
January 5, 2026
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
December 17, 2025
Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
November 26, 2025
Tango Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
November 12, 2025
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
November 4, 2025
Tango Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
October 29, 2025
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
October 23, 2025
Tango Therapeutics Announces $225 Million Financing
October 23, 2025
Tango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025
October 6, 2025
Tango Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
August 26, 2025
Tango Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
August 5, 2025
Tango Therapeutics to Report Second Quarter 2025 Financial Results on Tuesday, August 5, 2025
July 22, 2025
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines’ Daraxonrasib or Zoldonrasib in P...
June 27, 2025
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
May 27, 2025
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tu...
May 21, 2025
Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 12, 2025
Tango Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
May 1, 2025
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline with Five Posters at the American Association for Cancer ...
March 25, 2025
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights
February 27, 2025
Tango Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Highlights
February 27, 2025
Tango Therapeutics to Present at Three Upcoming Investment Bank Conferences
February 20, 2025
Tango Therapeutics to Present at the Guggenheim SMID Cap Biotechnology Conference
January 30, 2025
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 3, 2024
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
November 6, 2024
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 6, 2024
Tango Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 7, 2024
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 5, 2024
Tango Therapeutics Announces Discontinuation of TNG348 Program
May 23, 2024
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 8, 2024
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
March 18, 2024
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) An...
March 5, 2024
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
January 31, 2024
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
January 3, 2024
Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
November 13, 2023
Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
November 8, 2023
Tango Therapeutics to Present at the Jefferies London Healthcare Conference
November 7, 2023